

**Listing of Claims.**

Please amend the claims as shown below by deleting the material indicated by strike-through and adding the underlined material. This listing of claims will replace all prior versions and listings of the claims in this application.

Claims 1-88. (Canceled)

89. (Currently amended) The composition of Claim 104 ~~84~~, wherein each of said one or more heterologous nucleotide sequences is operably associated with a promoter.

90. (Previously presented) The composition of Claim 89, wherein said promoter operably associated with each of said one or more heterologous nucleotide sequences is an alphavirus 26S subgenomic promoter.

Claims 91-92. (Canceled).

93. (Currently amended) A pharmaceutical formulation comprising the composition of Claim 104 ~~84~~ in a pharmaceutically acceptable carrier.

Claims 94-96. (Canceled)

97. (Currently amended) The composition of Claim 104 ~~95~~, wherein at least one of said one or more attenuating mutations is selected from the group consisting of codons at E2 amino acid position 76 which specify an attenuating amino acid, codons at E2 amino acid position 120 which specify an attenuating amino acid, codons at E2 amino acid position 209 which specify an attenuating amino acid, codons at E1 amino acid 272 which specify an attenuating mutation, codons at E1 amino acid 81 which specify an

attenuating mutation, and codons at E1 amino acid 253 which specify an attenuating mutation, and the deletion of E3 amino acids 56-59.

Claims 98-103. (Canceled)

104. (Currently amended) A composition comprising infectious Venezuelan Equine Encephalitis (VEE) replicon particles ~~in an amount effective to provide a protective immune response~~, wherein said VEE replicon particles comprise one or more heterologous nucleotide sequences encoding a Her2 gene product, and wherein said VEE replicon particles infect antigen-presenting cells, and further wherein said VEE replicon particles comprise one or more attenuating mutations.

Claims 105-108 (Canceled).

109. (Currently amended) The composition of Claim 104 84, wherein said antigen-presenting cells are dendritic cells.

Claims 110-114. (Canceled)